{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T10:58:36Z","timestamp":1770721116363,"version":"3.49.0"},"reference-count":88,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"DOI":"10.1007\/s11239-025-03171-6","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T09:27:53Z","timestamp":1756459673000},"page":"210-219","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Missense and nonsense mutations and inhibitor development in patients with hemophilia A and B"],"prefix":"10.1007","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-1692-3512","authenticated-orcid":false,"given":"Fatemeh","family":"Karimi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8494-5594","authenticated-orcid":false,"given":"Najmaldin","family":"Saki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3121-9307","authenticated-orcid":false,"given":"Reyhane","family":"Khademi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0324-3238","authenticated-orcid":false,"given":"Gholam-Abbas","family":"Kaydani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3087-7650","authenticated-orcid":false,"given":"Bijan","family":"Keikhaei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"issue":"23","key":"3171_CR1","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1056\/NEJM200106073442307","volume":"344","author":"PM Mannucci","year":"2001","unstructured":"Mannucci PM, Tuddenham EG (2001) The hemophilias\u2013from Royal genes to gene therapy. N Engl J Med 344(23):1773\u20131779","journal-title":"N Engl J Med"},{"key":"3171_CR2","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1750-1172-7-24","volume":"7","author":"M Franchini","year":"2012","unstructured":"Franchini M, Mannucci PM (2012) Past, present and future of hemophilia: a narrative review. Orphanet J Rare Dis 7:24","journal-title":"Orphanet J Rare Dis"},{"issue":"9371","key":"3171_CR3","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1016\/S0140-6736(03)13405-8","volume":"361","author":"PH Bolton-Maggs","year":"2003","unstructured":"Bolton-Maggs PH, Pasi KJ (2003) Haemophilias A and B. Lancet 361(9371):1801\u20131809","journal-title":"Lancet"},{"issue":"3","key":"3171_CR4","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1046\/j.1365-2516.2002.00626.x","volume":"8","author":"D Dimichele","year":"2002","unstructured":"Dimichele D (2002) Inhibitors: resolving diagnostic and therapeutic dilemmas. Haemophilia 8(3):280\u2013287","journal-title":"Haemophilia"},{"issue":"3","key":"3171_CR5","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/j.1365-2141.2007.06657.x","volume":"138","author":"D DiMichele","year":"2007","unstructured":"DiMichele D (2007) Inhibitor development in haemophilia B: an orphan disease in need of attention. Br J Haematol 138(3):305\u2013315","journal-title":"Br J Haematol"},{"issue":"11","key":"3171_CR6","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1182\/blood-2013-02-483263","volume":"122","author":"CL Eckhardt","year":"2013","unstructured":"Eckhardt CL, Van Velzen AS, Peters M, Astermark J, Brons PP, Castaman G et al (2013) Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A. Blood 122(11):1954\u20131962","journal-title":"Blood"},{"issue":"4","key":"3171_CR7","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1002\/pbc.24856","volume":"61","author":"K Lindvall","year":"2014","unstructured":"Lindvall K, von Mackensen S, Elmst\u00e5hl S, Khair K, Stain AM, Ljung R, Berntorp E (2014) Increased burden on caregivers of having a child with haemophilia complicated by inhibitors. Pediatr Blood Cancer 61(4):706\u2013711","journal-title":"Pediatr Blood Cancer"},{"issue":"2","key":"3171_CR8","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/j.1365-2516.2011.02692.x","volume":"18","author":"S Guh","year":"2012","unstructured":"Guh S, Grosse S, McAlister S, Kessler C, Soucie J (2012) Healthcare expenditures for males with haemophilia and employer-sponsored insurance in the United States, 2008. Haemophilia 18(2):268\u2013275","journal-title":"Haemophilia"},{"issue":"8793","key":"3171_CR9","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/0140-6736(92)90874-3","volume":"339","author":"S Ehrenforth","year":"1992","unstructured":"Ehrenforth S, Kreuz W, Scharrer I, Linde R, Funk M, G\u00fcng\u00f6r T et al (1992) Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 339(8793):594\u2013598","journal-title":"Lancet"},{"issue":"6","key":"3171_CR10","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1055\/s-0038-1649954","volume":"74","author":"R Schwaab","year":"1995","unstructured":"Schwaab R, Brackmann HH, Meyer C, Seehafer J, Kirchgesser M, Haack A et al (1995) Haemophilia A: mutation type determines risk of inhibitor formation. Thromb Haemost 74(6):1402\u20131406","journal-title":"Thromb Haemost"},{"issue":"6","key":"3171_CR11","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1055\/s-0037-1613931","volume":"83","author":"AC Goodeve","year":"2000","unstructured":"Goodeve AC, Williams I, Bray GL, Peake IR (2000) Relationship between factor VIII mutation type and inhibitor development in a cohort of previously untreated patients treated with Recombinant factor VIII (Recombinate). Recombinate PUP study group. Thromb Haemost 83(6):844\u2013848","journal-title":"Thromb Haemost"},{"issue":"2","key":"3171_CR12","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1046\/j.1365-2516.1999.t01-1-00303.x","volume":"5","author":"E Thorland","year":"1999","unstructured":"Thorland E, Drost J, Lusher J, Warrier I, Shapiro A, Koerper M et al (1999) Anaphylactic response to factor IX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk. Haemophilia 5(2):101\u2013105","journal-title":"Haemophilia"},{"issue":"16","key":"3171_CR13","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1182\/blood-2016-02-701805","volume":"128","author":"G Batsuli","year":"2016","unstructured":"Batsuli G, Deng W, Healey JF, Parker ET, Baldwin WH, Cox C et al (2016) High-affinity, noninhibitory pathogenic C1 domain antibodies are present in patients with hemophilia A and inhibitors. Blood 128(16):2055\u20132067","journal-title":"Blood"},{"issue":"Suppl 6","key":"3171_CR14","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/hae.12467","volume":"20","author":"GD Minno","year":"2014","unstructured":"Minno GD, Santagostino E, Pratt K, K\u00f6nigs C (2014) New predictive approaches for ITI treatment. Haemophilia 20(Suppl 6):27\u201343","journal-title":"Haemophilia"},{"issue":"3","key":"3171_CR15","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.ejmhg.2017.10.004","volume":"19","author":"UA Ibrahim","year":"2018","unstructured":"Ibrahim UA, Ahmed SG (2018) Determinants and modifiers of bleeding phenotypes in haemophilia-A: general and tropical perspectives. Egypt J Med Hum Genet 19(3):171\u2013178","journal-title":"Egypt J Med Hum Genet"},{"issue":"22","key":"3171_CR16","doi-asserted-by":"publisher","first-page":"7728","DOI":"10.1073\/pnas.82.22.7728","volume":"82","author":"CA Fulcher","year":"1985","unstructured":"Fulcher CA, de Graaf Mahoney S, Roberts JR, Kasper CK, Zimmerman TS (1985) Localization of human factor FVIII inhibitor epitopes to two polypeptide fragments. Proc Natl Acad Sci U S A 82(22):7728\u20137732","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"3171_CR17","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1056\/NEJMoa011979","volume":"346","author":"S Lacroix-Desmazes","year":"2002","unstructured":"Lacroix-Desmazes S, Bayry J, Misra N, Horn MP, Villard S, Pashov A et al (2002) The prevalence of proteolytic antibodies against factor VIII in hemophilia A. N Engl J Med 346(9):662\u2013667","journal-title":"N Engl J Med"},{"key":"3171_CR18","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s12016-009-8118-1","volume":"37","author":"K Ghosh","year":"2009","unstructured":"Ghosh K, Shetty S (2009) Immune response to FVIII in hemophilia A: an overview of risk factors. Clin Rev Allergy Immunol 37:58\u201366","journal-title":"Clin Rev Allergy Immunol"},{"issue":"4","key":"3171_CR19","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/(SICI)1096-8652(199812)59:4<288::AID-AJH4>3.0.CO;2-I","volume":"59","author":"JM Soucie","year":"1998","unstructured":"Soucie JM, Evatt B, Jackson D, Investigators HSSP (1998) Occurrence of hemophilia in the United States. Am J Hematol 59(4):288\u2013294","journal-title":"Am J Hematol"},{"issue":"4","key":"3171_CR20","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1111\/j.1365-2141.2004.05168.x","volume":"127","author":"NS Key","year":"2004","unstructured":"Key NS (2004) Inhibitors in congenital coagulation disorders. Br J Haematol 127(4):379\u2013391","journal-title":"Br J Haematol"},{"issue":"5","key":"3171_CR21","doi-asserted-by":"publisher","first-page":"e305","DOI":"10.1016\/j.ijid.2011.01.004","volume":"15","author":"H-Q Qu","year":"2011","unstructured":"Qu H-Q, Fisher-Hoch SP, McCormick JB (2011) Molecular immunity to mycobacteria: knowledge from the mutation and phenotype spectrum analysis of Mendelian susceptibility to mycobacterial diseases. Int J Infect Dis 15(5):e305\u2013e13","journal-title":"Int J Infect Dis"},{"key":"3171_CR22","first-page":"721","volume-title":"Molecular biology (Second Edition)","author":"DP Clark","year":"2013","unstructured":"Clark DP, Pazdernik NJ (2013) Chapter 23 - Mutations and repair. In: Clark DP, Pazdernik NJ (eds) Molecular biology (Second Edition). Academic, Boston, pp 721\u2013766"},{"issue":"5992","key":"3171_CR23","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/312342a0","volume":"312","author":"JJ Toole","year":"1984","unstructured":"Toole JJ, Knopf JL, Wozney JM, Sultzman LA, Buecker JL, Pittman DD et al (1984) Molecular cloning of a cDNA encoding human antihaemophilic factor. Nature 312(5992):342\u2013347","journal-title":"Nature"},{"key":"3171_CR24","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V74.5.1618.1618","author":"D Scandella","year":"1989","unstructured":"Scandella D, Mattingly M, de Graaf S, Fulcher CA (1989) Localization of epitopes for human factor VIII inhibitor antibodies by immunoblotting and antibody neutralization. Blood. https:\/\/doi.org\/10.1182\/blood.V74.5.1618.1618","journal-title":"Blood"},{"issue":"06","key":"3171_CR25","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1055\/s-0038-1648520","volume":"67","author":"D Scandella","year":"1992","unstructured":"Scandella D, Timmons L, Mattingly M, Trabold N, Hoyer LW (1992) A soluble recombinant factor VIII fragment containing the A2 domain binds to some human anti-factor VIII antibodies that are not detected by immunoblotting. Thromb Haemost 67(06):665\u2013671","journal-title":"Thromb Haemost"},{"key":"3171_CR26","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.5.1811.bloodjournal8651811","author":"D Scandella","year":"1995","unstructured":"Scandella D, Gilbert GE, Shima M, Nakai H, Eagleson C, Felch M et al (1995) Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site. Blood. https:\/\/doi.org\/10.1182\/blood.V86.5.1811.bloodjournal8651811","journal-title":"Blood"},{"issue":"24","key":"3171_CR27","doi-asserted-by":"publisher","first-page":"14505","DOI":"10.1074\/jbc.270.24.14505","volume":"270","author":"JF Healey","year":"1995","unstructured":"Healey JF, Lubin IM, Nakai H, Saenko EL, Hoyer LW, Scandella D, Lollar P (1995) Residues 484\u2013508 contain a major determinant of the inhibitory epitope in the A2 domain of human factor VIII. J Biol Chem 270(24):14505\u201314509","journal-title":"J Biol Chem"},{"issue":"2","key":"3171_CR28","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1055\/s-2000-9819","volume":"26","author":"SS Fakharzadeh","year":"2000","unstructured":"Fakharzadeh SS, Kazazian HH Jr (2000) Correlation between factor VIII genotype and inhibitor development in hemophilia A. Semin Thromb Hemost 26(2):167\u2013171","journal-title":"Semin Thromb Hemost"},{"issue":"6","key":"3171_CR29","doi-asserted-by":"publisher","first-page":"e402","DOI":"10.1111\/hae.12491","volume":"20","author":"F Iioka","year":"2014","unstructured":"Iioka F, Shimomura D, Nakamura F, Ohno H, Yada K, Nogami K, Shima M (2014) Long-term treatment course of a patient with mild haemophilia A who developed a high titre factor VIII inhibitor. Haemophilia 20(6):e402\u2013e404","journal-title":"Haemophilia"},{"issue":"1","key":"3171_CR30","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/j.1365-2516.2009.02081.x","volume":"16","author":"A AWIDI","year":"2010","unstructured":"AWIDI A, RAMAHI M, AlHATTAB D, MEFLEH R, DWEIRI M, BSOUL N et al (2010) Study of mutations in Jordanian patients with haemophilia A: identification of five novel mutations. Haemophilia 16(1):136\u2013142","journal-title":"Haemophilia"},{"issue":"06","key":"3171_CR31","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1055\/s-0037-1613931","volume":"83","author":"AC Goodeve","year":"2000","unstructured":"Goodeve AC, Williams I, Bray GL, Peake IR, Group RPS (2000) Relationship between factor VIII mutation type and inhibitor development in a cohort of previously untreated patients treated with Recombinant factor VIII (Recombinate\u2122). Thromb Haemost 83(06):844\u2013848","journal-title":"Thromb Haemost"},{"issue":"1","key":"3171_CR32","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1111\/j.1365-2141.2008.07310.x","volume":"143","author":"P Green","year":"2008","unstructured":"Green P, Bagnall R, Waseem N, Giannelli F (2008) Haemophilia a mutations in the UK: results of screening one-third of the population. Br J Haematol 143(1):115\u2013128","journal-title":"Br J Haematol"},{"issue":"3","key":"3171_CR33","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1111\/j.1365-2516.2011.02700.x","volume":"18","author":"C Miller","year":"2012","unstructured":"Miller C, Benson J, Ellingsen D, Driggers J, Payne A, Kelly F et al (2012) F8 and F9 mutations in US haemophilia patients: correlation with history of inhibitor and race\/ethnicity. Haemophilia 18(3):375\u2013382","journal-title":"Haemophilia"},{"issue":"07","key":"3171_CR34","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1160\/TH09-11-0795","volume":"104","author":"S Reitter","year":"2010","unstructured":"Reitter S, Sturn R, Horvath B, Freitag R, Male C, Muntean W et al (2010) Spectrum of causative mutations in patients with haemophilia A in Austria. Thromb Haemost 104(07):78\u201385","journal-title":"Thromb Haemost"},{"issue":"7","key":"3171_CR35","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1111\/j.1538-7836.2007.02591.x","volume":"5","author":"Y Repesse","year":"2007","unstructured":"Repesse Y, Slaoui M, Ferrandiz D, Gautier P, Costa C, Costa J et al (2007) Factor VIII (FVIII) gene mutations in 120 patients with hemophilia A: detection of 26 novel mutations and correlation with FVIII inhibitor development. J Thromb Haemost 5(7):1469\u20131476","journal-title":"J Thromb Haemost"},{"issue":"9","key":"3171_CR36","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1002\/ajh.23269","volume":"87","author":"CL Kempton","year":"2012","unstructured":"Kempton CL, Allen G, Hord J, Kruse-Jarres R, Pruthi RK, Walsh C et al (2012) Eradication of factor VIII inhibitors in patients with mild and moderate hemophilia a. Am J Hematol 87(9):933\u2013936","journal-title":"Am J Hematol"},{"issue":"3","key":"3171_CR37","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1160\/TH12-07-0521","volume":"109","author":"R Schwaab","year":"2013","unstructured":"Schwaab R, Pavlova A, Albert T, Caspers M, Oldenburg J (2013) Significance of F8 missense mutations with respect to inhibitor formation. Thromb Haemost 109(3):464\u2013470","journal-title":"Thromb Haemost"},{"issue":"1","key":"3171_CR38","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/hae.12229","volume":"20","author":"J Puetz","year":"2014","unstructured":"Puetz J, Soucie JM, Kempton CL, Monahan PE (2014) Prevalent inhibitors in haemophilia B subjects enrolled in the universal data collection database. Haemophilia 20(1):25\u201331","journal-title":"Haemophilia"},{"issue":"4","key":"3171_CR39","doi-asserted-by":"publisher","first-page":"252","DOI":"10.5045\/br.2021.2021016","volume":"56","author":"S Kulkarni","year":"2021","unstructured":"Kulkarni S, Hegde R, Hegde S, Kulkarni SS, Hanagvadi S, Das KK et al (2021) Mutation analysis and characterisation of F9 gene in haemophilia- B population of India. Blood Res 56(4):252\u2013258","journal-title":"Blood Res"},{"issue":"1","key":"3171_CR40","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3324\/haematol.2019.239160","volume":"106","author":"C Male","year":"2021","unstructured":"Male C, Andersson NG, Rafowicz A, Liesner R, Kurnik K, Fischer K et al (2021) Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet study. Haematologica 106(1):123\u2013129","journal-title":"Haematologica"},{"issue":"7","key":"3171_CR41","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.1111\/jth.12958","volume":"13","author":"AC Goodeve","year":"2015","unstructured":"Goodeve AC (2015) Hemophilia B: molecular pathogenesis and mutation analysis. J Thromb Haemost 13(7):1184\u20131195","journal-title":"J Thromb Haemost"},{"issue":"1","key":"3171_CR42","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13052-015-0116-8","volume":"41","author":"A Bon","year":"2015","unstructured":"Bon A, Morfini M, Dini A, Mori F, Barni S, Gianluca S et al (2015) Desensitization and immune tolerance induction in children with severe factor IX deficiency; inhibitors and adverse reactions to replacement therapy: a case-report and literature review. Ital J Pediatr 41(1):12","journal-title":"Ital J Pediatr"},{"key":"3171_CR43","doi-asserted-by":"crossref","unstructured":"Guttman B, Mutation (2013) Nonsense. In: Maloy S, Hughes K, editors. Brenner\u2019s Encyclopedia of Genetics (Second Edition). San Diego: Academic Press; p. 548","DOI":"10.1016\/B978-0-12-374984-0.01005-6"},{"issue":"2","key":"3171_CR44","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3324\/haematol.2022.281279","volume":"108","author":"MF Testa","year":"2023","unstructured":"Testa MF, Lombardi S, Bernardi F, Ferrarese M, Belvini D, Radossi P et al (2023) Translational readthrough at F8 nonsense variants in the factor VIII B domain contributes to residual expression and lowers inhibitor association. Haematologica 108(2):472\u2013482","journal-title":"Haematologica"},{"issue":"4","key":"3171_CR45","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1007\/BF01897781","volume":"33","author":"S Mikami","year":"1988","unstructured":"Mikami S, Nishimura T, Naka H, Kuze K, Fukui H, Tone M, Hashimoto-Gotoh T (1988) Nonsense mutation in factor VIII gene of a severe haemophiliac patient with anti-factor VIII antibody. Jinrui Idengaku Zasshi 33(4):409\u2013415","journal-title":"Jinrui Idengaku Zasshi"},{"issue":"3","key":"3171_CR46","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/S0888-7543(05)80155-7","volume":"14","author":"B Levinson","year":"1992","unstructured":"Levinson B, Kenwrick S, Gamel P, Fisher K, Gitschier J (1992) Evidence for a third transcript from the human factor VIII gene. Genomics 14(3):585\u2013589","journal-title":"Genomics"},{"issue":"4","key":"3171_CR47","doi-asserted-by":"publisher","DOI":"10.1002\/rth2.12723","volume":"6","author":"J Sun","year":"2022","unstructured":"Sun J, Li Z, Huang K, Ai D, Li G, Xie X et al (2022) F8 gene mutation spectrum in severe hemophilia A with inhibitors: a large cohort data analysis from a single center in China. Res Pract Thromb Haemost 6(4):e12723","journal-title":"Res Pract Thromb Haemost"},{"issue":"4","key":"3171_CR48","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1111\/jth.13961","volume":"16","author":"S Spena","year":"2018","unstructured":"Spena S, Garagiola I, Cannav\u00f2 A, Mortarino M, Mannucci PM, Rosendaal FR, Peyvandi F (2018) Prediction of factor VIII inhibitor development in the SIPPET cohort by mutational analysis and factor VIII antigen measurement. J Thromb Haemost 16(4):778\u2013790","journal-title":"J Thromb Haemost"},{"issue":"12","key":"3171_CR49","doi-asserted-by":"publisher","first-page":"2922","DOI":"10.1182\/blood-2011-09-379453","volume":"119","author":"SC Gouw","year":"2012","unstructured":"Gouw SC, van den Berg HM, Oldenburg J, Astermark J, de Groot PG, Margaglione M et al (2012) F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis. Blood 119(12):2922\u20132934","journal-title":"Blood"},{"issue":"8","key":"3171_CR50","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1002\/humu.20763","volume":"29","author":"M Mort","year":"2008","unstructured":"Mort M, Ivanov D, Cooper DN, Chuzhanova NA (2008) A meta-analysis of nonsense mutations causing human genetic disease. Hum Mutat 29(8):1037\u20131047","journal-title":"Hum Mutat"},{"key":"3171_CR51","first-page":"635","volume":"90 5","author":"D Belvini","year":"2005","unstructured":"Belvini D, Salviato R, Radossi P, Pierobon F, Mori PG, Castaldo G, Tagariello G (2005) Molecular genotyping of the Italian cohort of patients with hemophilia B. Haematologica 90 5:635\u2013642","journal-title":"Haematologica"},{"issue":"4","key":"3171_CR52","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1002\/ajh.23645","volume":"89","author":"T Li","year":"2014","unstructured":"Li T, Miller CH, Driggers J, Payne AB, Ellingsen D, Hooper WC (2014) Mutation analysis of a cohort of US patients with hemophilia B. Am J Hematol 89(4):375\u2013379","journal-title":"Am J Hematol"},{"issue":"1","key":"3171_CR53","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1186\/s13287-022-03036-2","volume":"13","author":"Y Ma","year":"2022","unstructured":"Ma Y, Sun W, Zhao L, Yao M, Wu C, Su P et al (2022) Generation of an mESC model with a human hemophilia B nonsense mutation via CRISPR\/Cas9 technology. Stem Cell Res Ther 13(1):353","journal-title":"Stem Cell Res Ther"},{"issue":"9","key":"3171_CR54","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1111\/j.1538-7836.2009.03538.x","volume":"7","author":"B Waters","year":"2009","unstructured":"Waters B, Lillicrap D (2009) The molecular mechanisms of immunomodulation and tolerance induction to factor VIII. J Thromb Haemost 7(9):1446\u20131456","journal-title":"J Thromb Haemost"},{"issue":"23","key":"3171_CR55","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1182\/blood-2014-05-577643","volume":"124","author":"CL Kempton","year":"2014","unstructured":"Kempton CL, Meeks SL (2014) Toward optimal therapy for inhibitors in hemophilia. Blood 124(23):3365\u20133372","journal-title":"Blood"},{"key":"3171_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1111\/j.1365-2516.2007.01497.x","volume":"13","author":"DM Dimichele","year":"2007","unstructured":"Dimichele DM, Hoots W, Pipe SW, Rivard G, Santagostino E (2007) International workshop on immune tolerance induction: consensus recommendations 1. Haemophilia 13:1\u201322","journal-title":"Haemophilia"},{"issue":"01","key":"3171_CR57","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0037-1612943","volume":"87","author":"DM DiMichele","year":"2002","unstructured":"DiMichele DM, Kroner B, the, Group NAITS (2002) The North American immune tolerance registry: practices, outcomes, outcome predictors. Thromb Haemost 87(01):52\u201357","journal-title":"Thromb Haemost"},{"issue":"6","key":"3171_CR58","first-page":"1335","volume":"119","author":"CR Hay","year":"2012","unstructured":"Hay CR, DiMichele DM (2012) The principal results of the international immune tolerance study: a randomized dose comparison. Blood J Am Soc Hematol 119(6):1335\u20131344","journal-title":"Blood J Am Soc Hematol"},{"issue":"11","key":"3171_CR59","first-page":"1186","volume":"86","author":"G Mariani","year":"2001","unstructured":"Mariani G, Kroner B, Group ITS (2001) Immune tolerance in hemophilia with factor VIII inhibitors: predictors of success. Haematologica 86(11):1186\u20131193","journal-title":"Haematologica"},{"key":"3171_CR60","doi-asserted-by":"crossref","unstructured":"Batorova A, Morongova A, Tagariello G, Jankovicova D, Prigancova T, Horakova J (eds) (2013) Challenges in the management of hemophilia B with inhibitor. Seminars in thrombosis and hemostasis. Thieme Medical","DOI":"10.1055\/s-0033-1356574"},{"issue":"3","key":"3171_CR61","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1046\/j.1365-2516.2003.00772.x","volume":"9","author":"M Shibata","year":"2003","unstructured":"Shibata M, Shima M, Misu H, Okimoto Y, Giddings J, Yoshioka A (2003) Management of haemophilia B inhibitor patients with anaphylactic reactions to FIX concentrates. Haemophilia 9(3):269\u2013271","journal-title":"Haemophilia"},{"key":"3171_CR62","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13052-015-0116-8","volume":"41","author":"A Bon","year":"2015","unstructured":"Bon A, Morfini M, Dini A, Mori F, Barni S, Gianluca S et al (2015) Desensitization and immune tolerance induction in children with severe factor IX deficiency; inhibitors and adverse reactions to replacement therapy: a case-report and literature review. Ital J Pediatr 41:1\u20135","journal-title":"Ital J Pediatr"},{"issue":"5","key":"3171_CR63","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1111\/hae.12730","volume":"21","author":"L Valentino","year":"2015","unstructured":"Valentino L, Kempton C, Kruse-Jarres R, Mathew P, Meeks S, Reiss U, Investigators IITIS (2015) US guidelines for immune tolerance induction in patients with haemophilia a and inhibitors. Haemophilia 21(5):559\u2013567","journal-title":"Haemophilia"},{"issue":"2","key":"3171_CR64","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1111\/bjh.12091","volume":"160","author":"PW Collins","year":"2013","unstructured":"Collins PW, Chalmers E, Hart DP, Liesner R, Rangarajan S, Talks K et al (2013) Diagnosis and treatment of factor <scp>VIII<\/scp>and <scp>IX<\/scp>inhibitors in congenital haemophilia: (4th edition). Br J Haematol 160(2):153\u2013170","journal-title":"Br J Haematol"},{"issue":"24","key":"3171_CR65","doi-asserted-by":"publisher","first-page":"3706","DOI":"10.1182\/blood-2014-02-555151","volume":"123","author":"SA Fahs","year":"2014","unstructured":"Fahs SA, Hille MT, Shi Q, Weiler H, Montgomery RR (2014) A conditional knockout mouse model reveals endothelial cells as the principal and possibly exclusive source of plasma factor VIII. Blood 123(24):3706\u20133713","journal-title":"Blood"},{"issue":"24","key":"3171_CR66","doi-asserted-by":"publisher","first-page":"3697","DOI":"10.1182\/blood-2014-02-554501","volume":"123","author":"LA Everett","year":"2014","unstructured":"Everett LA, Cleuren AC, Khoriaty RN, Ginsburg D (2014) Murine coagulation factor VIII is synthesized in endothelial cells. Blood 123(24):3697\u20133705","journal-title":"Blood"},{"issue":"1","key":"3171_CR67","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jaut.2009.08.008","volume":"34","author":"G Tiegs","year":"2010","unstructured":"Tiegs G, Lohse AW (2010) Immune tolerance: what is unique about the liver. J Autoimmun 34(1):1\u20136","journal-title":"J Autoimmun"},{"issue":"1","key":"3171_CR68","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/nri981","volume":"3","author":"IN Crispe","year":"2003","unstructured":"Crispe IN (2003) Hepatic T cells and liver tolerance. Nat Rev Immunol 3(1):51\u201362","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"3171_CR69","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1038\/mt.2010.240","volume":"19","author":"DE Sabatino","year":"2011","unstructured":"Sabatino DE, Lange AM, Altynova ES, Sarkar R, Zhou S, Merricks EP et al (2011) Efficacy and safety of long-term prophylaxis in severe hemophilia A dogs following liver gene therapy using AAV vectors. Mol Ther 19(3):442\u2013449","journal-title":"Mol Ther"},{"issue":"1","key":"3171_CR70","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1182\/blood.V97.1.107","volume":"97","author":"AM Gallo-Penn","year":"2001","unstructured":"Gallo-Penn AM, Shirley PS, Andrews JL, Tinlin S, Webster S, Cameron C et al (2001) Systemic delivery of an adenoviral vector encoding canine factor VIII results in short-term phenotypic correction, inhibitor development, and biphasic liver toxicity in hemophilia A dogs. Blood 97(1):107\u2013113","journal-title":"Blood"},{"issue":"26","key":"3171_CR71","doi-asserted-by":"publisher","first-page":"5842","DOI":"10.1182\/blood-2010-06-288001","volume":"116","author":"JD Finn","year":"2010","unstructured":"Finn JD, Ozelo MC, Sabatino DE, Franck HW, Merricks EP, Crudele JM et al (2010) Eradication of neutralizing antibodies to factor VIII in canine hemophilia A after liver gene therapy. Blood 116(26):5842\u20135848","journal-title":"Blood"},{"issue":"11","key":"3171_CR72","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1111\/j.1538-7836.2009.03615.x","volume":"7","author":"A Coppola","year":"2009","unstructured":"Coppola A, Margaglione M, Santagostino E, Rocino A, Grandone E, Mannucci P et al (2009) Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophilia A patients with high-responding inhibitors. J Thromb Haemost 7(11):1809\u20131815","journal-title":"J Thromb Haemost"},{"issue":"4","key":"3171_CR73","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1182\/blood-2003-08-2954","volume":"103","author":"R Sarkar","year":"2004","unstructured":"Sarkar R, Tetreault R, Gao G, Wang L, Bell P, Chandler R et al (2004) Total correction of hemophilia A mice with canine FVIII using an AAV 8 serotype. Blood 103(4):1253\u20131260","journal-title":"Blood"},{"key":"3171_CR74","unstructured":"Siner J, Samelson-Jones B, Crudele J, Zhou S, Merricks E, Nichols T et al (eds) (2015) Enhanced factor VIII gene therapy for hemophilia A dogs with a novel furin-evading factor VIII variant. Journal of Thrombosis and Haemostasis; : WILEY-BLACKWELL 111 RIVER ST, HOBOKEN 07030\u2009\u2013\u20095774, NJ USA"},{"issue":"5","key":"3171_CR75","doi-asserted-by":"publisher","first-page":"e37671","DOI":"10.1371\/journal.pone.0037671","volume":"7","author":"BK Sack","year":"2012","unstructured":"Sack BK, Merchant S, Markusic DM, Nathwani AC, Davidoff AM, Byrne BJ, Herzog RW (2012) Transient B cell depletion or improved transgene expression by codon optimization promote tolerance to factor VIII in gene therapy. PLoS One 7(5):e37671","journal-title":"PLoS One"},{"issue":"5","key":"3171_CR76","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1038\/mt.2010.274","volume":"19","author":"AC Nathwani","year":"2011","unstructured":"Nathwani AC, Rosales C, McIntosh J, Rastegarlari G, Nathwani D, Raj D et al (2011) Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins. Mol Ther 19(5):876\u2013885","journal-title":"Mol Ther"},{"key":"3171_CR77","unstructured":"Monahan P, Walsh C, Powell J, Konkle B, Josephson N, Escobar M et al (eds) (2015) Update on a phase 1\/2 open-label trial of BAX335, an adeno-associated virus 8 (AAV8) vector-based gene therapy program for hemophilia B. Journal of Thrombosis and Haemostasis; : WILEY-BLACKWELL 111 RIVER ST, HOBOKEN 07030\u2009\u2013\u20095774, NJ USA"},{"issue":"10","key":"3171_CR78","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1182\/blood-2014-07-588194","volume":"125","author":"JM Crudele","year":"2015","unstructured":"Crudele JM, Finn JD, Siner JI, Martin NB, Niemeyer GP, Zhou S et al (2015) AAV liver expression of FIX-Padua prevents and eradicates FIX inhibitor without increasing thrombogenicity in hemophilia B dogs and mice. Blood 125(10):1553\u20131561","journal-title":"Blood"},{"issue":"7","key":"3171_CR79","doi-asserted-by":"publisher","first-page":"2334","DOI":"10.1182\/blood-2007-03-080093","volume":"110","author":"F Mingozzi","year":"2007","unstructured":"Mingozzi F, Hasbrouck NC, Basner-Tschakarjan E, Edmonson SA, Hui DJ, Sabatino DE et al (2007) Modulation of tolerance to the transgene product in a nonhuman primate model of AAV-mediated gene transfer to liver. Blood 110(7):2334\u20132341","journal-title":"Blood"},{"issue":"9","key":"3171_CR80","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1172\/JCI200316887","volume":"111","author":"F Mingozzi","year":"2003","unstructured":"Mingozzi F, Liu Y-L, Dobrzynski E, Kaufhold A, Liu JH, Wang Y et al (2003) Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer. J Clin Invest 111(9):1347\u20131356","journal-title":"J Clin Invest"},{"issue":"11","key":"3171_CR81","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1002\/emmm.201302859","volume":"5","author":"DM Markusic","year":"2013","unstructured":"Markusic DM, Hoffman BE, Perrin GQ, Nayak S, Wang X, LoDuca PA et al (2013) Effective gene therapy for haemophilic mice with pathogenic factor <scp>IX<\/scp>antibodies. EMBO Mol Med 5(11):1698\u20131709","journal-title":"EMBO Mol Med"},{"issue":"1","key":"3171_CR82","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1182\/asheducation-2014.1.461","volume":"2014","author":"CB Doering","year":"2014","unstructured":"Doering CB, Spencer HT (2014) Replacing bad (F)actors: hemophilia. Hematol Am Soc Hematol Educ Program 2014(1):461\u2013467","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"4","key":"3171_CR83","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1002\/jgm.1442","volume":"12","author":"LM Ide","year":"2010","unstructured":"Ide LM, Iwakoshi NN, Gangadharan B, Jobe S, Moot R, McCarty D et al (2010) Functional aspects of factor VIII expression after transplantation of genetically-modified hematopoietic stem cells for hemophilia A. J Gene Med 12(4):333\u2013344","journal-title":"J Gene Med"},{"issue":"8","key":"3171_CR84","doi-asserted-by":"publisher","first-page":"2855","DOI":"10.1182\/blood-2007-04-082602","volume":"110","author":"LM Ide","year":"2007","unstructured":"Ide LM, Gangadharan B, Chiang KY, Doering CB, Spencer HT (2007) Hematopoietic stem-cell gene therapy of hemophilia A incorporating a porcine factor VIII transgene and nonmyeloablative conditioning regimens. Blood 110(8):2855\u20132863","journal-title":"Blood"},{"issue":"1","key":"3171_CR85","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1111\/j.1365-2516.2009.02099.x","volume":"16","author":"J Uprichard","year":"2010","unstructured":"Uprichard J, Dazzi F, Apperley JF, Laffan MA (2010) Haemopoietic stem cell transplantation induces tolerance to donor antigens but not to foreign FVIII peptides. Haemophilia 16(1):143\u2013147","journal-title":"Haemophilia"},{"issue":"7","key":"3171_CR86","doi-asserted-by":"publisher","first-page":"1974","DOI":"10.1172\/JCI28416","volume":"116","author":"Q Shi","year":"2006","unstructured":"Shi Q, Wilcox DA, Fahs SA, Weiler H, Wells CW, Cooley BC et al (2006) Factor VIII ectopically targeted to platelets is therapeutic in hemophilia A with high-titer inhibitory antibodies. J Clin Invest 116(7):1974\u20131982","journal-title":"J Clin Invest"},{"issue":"7","key":"3171_CR87","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1111\/j.1538-7836.2008.02992.x","volume":"6","author":"J Gewirtz","year":"2008","unstructured":"Gewirtz J, Thornton MA, Rauova L, Poncz M (2008) Platelet-delivered factor VIII provides limited resistance to anti-factor VIII inhibitors. J Thromb Haemost 6(7):1160\u20131166","journal-title":"J Thromb Haemost"},{"issue":"4","key":"3171_CR88","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/mt.2015.20","volume":"23","author":"X Wang","year":"2015","unstructured":"Wang X, Shin SC, Chiang AF, Khan I, Pan D, Rawlings DJ, Miao CH (2015) Intraosseous delivery of lentiviral vectors targeting factor VIII expression in platelets corrects murine hemophilia A. Mol Ther 23(4):617\u2013626","journal-title":"Mol Ther"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-025-03171-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-025-03171-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-025-03171-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T15:04:54Z","timestamp":1770649494000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-025-03171-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":88,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["3171"],"URL":"https:\/\/doi.org\/10.1007\/s11239-025-03171-6","relation":{},"ISSN":["1573-742X"],"issn-type":[{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,29]]},"assertion":[{"value":"12 August 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}